stockrow
Friday 6 November 2026
Export ATYR’s income statement to Excel — free account
aTyr Pharma, Inc.
ATYR Healthcare Biotechnology
aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024.
- Revenue
- −90.8%
- EPS
- +51.5%
- Free cash flow
- +32.2%
- Total debt
- −94.0%
Quarter to June 2026, against a year earlier
6.28
0.25
+4.15%
Follow ATYR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 10 | — | 10 | 0 | 0 | 0 | 11 | (12.5%) | 2 | 2 | 2 | +116.6% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 1.72 | +100.0 pt | ||||||
| EBT | (58) | (48) | (35) | (24) | (16) | (34) | (45) | (50) | (64) | (74) | (61) | +2.8% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | (5,631.04) | (155.24) | 0.00 | (436.58) | (14,276.77) | (27,243.40) | (39,012.11) | 0.00 | (39,012.1) pt | ||||||
| Net income | (58) | (48) | (35) | (24) | (16) | (34) | (45) | (50) | (64) | (74) | (61) | +2.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 5.03 | 45.66 | 0.00 | 14.62 | 0.26 | 0.13 | 0.08 | 0.00 | n/m | |||||
| Earnings | (1,368.68) | (1,045.14) | (644.54) | (283.26) | (70.87) | (70.81) | (63.82) | (37.61) | (34.48) | (31.89) | (24.94) | (34.1%) | ||||||
| Cash flow | (1,249.67) | (918.96) | (579.53) | (238.53) | (66.82) | (69.34) | (58.95) | (24.79) | (37.23) | (26.67) | (22.25) | (34.8%) | ||||||
| Capex | (14.18) | (28.46) | (11.08) | (0.33) | (0.80) | (0.30) | (2.06) | (3.13) | (0.03) | (0.03) | (0.11) | (49.9%) | ||||||
| Free cash flow | (1,263.85) | (947.42) | (590.62) | (238.87) | (67.62) | (69.64) | (61.01) | (27.92) | (37.26) | (26.69) | (22.35) | (34.9%) | ||||||
| Book value | 1,484.66 | 1,393.60 | 627.80 | 250.61 | 137.48 | 228.78 | 100.33 | 67.50 | 37.61 | 28.95 | 19.82 | (35.4%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | +56.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 0.00 | 3.40 | — | 5.25 | 6.19 | 20.64 | 6.52 | 1.38 | 7.0 | ||||||
| P/B | — | — | — | 0.67 | 1.13 | — | 0.94 | 0.89 | 3.85 | 1.08 | 0.32 | 1.4 | ||||||
| EV/Sales | — | — | — | 0.00 | 0.79 | — | 0.39 | (1.05) | 15.40 | (0.23) | (3.49) | 2.6 | ||||||
| EV/FCF | — | — | — | 0.27 | (0.54) | — | (0.12) | 0.36 | (2.90) | 0.04 | 0.71 | (0.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (53) | (42) | (31) | (20) | (15) | (33) | (42) | (33) | (69) | (62) | (55) | +1.8% | |||||
| Capex | (1) | (1) | (1) | 0 | 0 | 0 | (1) | (4) | 0 | 0 | 0 | (21.9%) | ||||||
| Free cash flow | (53) | (44) | (32) | (20) | (15) | (33) | (43) | (37) | (69) | (62) | (55) | +1.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 66 | 77 | 40 | 19 | 30 | 108 | 67 | 87 | 67 | 65 | 47 | (0.2%) | |||||
| Net debt | (63) | (65) | (34) | (29) | (30) | (108) | (65) | (97) | (71) | (78) | (57) | +2.5% | ||||||
| Shareholders’ equity | 63 | 64 | 34 | 21 | 31 | 109 | 71 | 90 | 70 | 67 | 49 | +0.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (55.05) | (56.75) | (48.58) | (53.08) | (43.31) | (43.78) | (42.91) | (46.56) | (58.88) | (78.09) | (70.97) | (23.0) pt | |||||
| ROIC | (18,959.42) | 0.00 | (15,194.44) | 0.00 | (847.77) | (1,318.00) | (471.97) | 0.00 | 0.00 | 0.00 | 0.00 | +18,959.4 pt | ||||||
| ROE | (65.06) | (75.89) | (70.52) | (86.34) | (61.80) | (48.03) | (50.26) | (62.30) | (79.88) | (108.11) | (98.67) | (43.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 58 | 65 | 42 | 44 | 43 | 53 | 70 | 59 | 59 | 58 | — | 0.0% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.01 | 0.24 | 0.00 | 0.15 | 0.01 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2025 · fundamentals updated 2 Nov 2026
aTyr Pharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $15.5M | — (loss-making) | — | — | n/m | +12.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $15.3M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| PLUR Pluri Inc. | $15.0M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| NEUP Neuphoria Therapeutics Inc. | $15.0M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $14.9M | — (loss-making) | — (loss-making) | −51.00% (below 0%: shrinking) | n/m | −97.84% (below 0%: shrinking) | 209.68% | 0.00% | Compare |
| KYNB Kyntra Bio Inc | $14.8M | 0.1× | — (loss-making) | −209.35% (below 0%: shrinking) | n/m | −131.50% (below 0%: shrinking) | 100.14% | 1,192.27% | Compare |
| ATYR aTyr Pharma, Inc. | $14.8M | — (loss-making) | — (loss-making) | −90.75% (below 0%: shrinking) | n/m | +32.22% (above 0%: growing) | 100.00% | 0.00% | |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | — (loss-making) | — (loss-making) | −89.33% (below 0%: shrinking) | n/m | −174.72% (below 0%: shrinking) | 81.71% | (221.45%) | Compare |
| Median of peers | $15.0M | — | — | −94.78% | — | −23.96% | 74.39% | 0.00% |
Pay and ownership Proxy statement filed 11 September 2026
Ownership
Directors and executive officers, together
5.03%
1001 Liberty AvenuePittsburgh, PA
8.68%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement